Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939958 | 0.85 | MEN1 (0.53) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6944186 | 0.81 | MEN1 (0.50) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6947003 | 0.78 | NOS2 (0.54) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL22162810 | 0.77 | MEN1 (0.64) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6944845 | 0.77 | NOS2 (0.54) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6945142 | 0.73 | NPC1 (0.47) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6943483 | 0.73 | NOS2 (1.00) | NOS2MAOBALDH1A1MAPK1MAOA | |
| SCHEMBL7304296 | 0.73 | MAPK1 (0.51) | NOS2KMT2AMEN1MAOBALDH1A1 | |
| SCHEMBL6165864 | 0.72 | ALDH1A1 (0.78) | KMT2AMEN1MAOBALDH1A1MAPK1 | |
| SCHEMBL11379943 | 0.71 | MAOB (0.50) | NOS2KMT2AMEN1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268471-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-6525051-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| EP-1268471-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | US | disclosed |
| WO-2001072744-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010190-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS3, NOS2 | NOS2 3/4885KMT2A 2660/4885MEN1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.